tbuckley/cabot-search huggingface dataset:
Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report
Authors: G. Schilling, G. Schuch, J. P. Panse, M. Sterneck, C. Bokemeyer
Journal: Journal of Clinical Oncology (2009)

e21527 Background: HEH is a rare tumor of the liver with an unpredictable malignant potential. Surgical resection or liver transplantation is recommended in locally advanced disease and has been successfully performed in selected cases with extrahepatic manifestations. Systemic therapy, however, is not standardized. Small cohorts have been treated with interferon, chemotherapy and angiogenesis inhibitors such as thalidomide with various results. Case report: A 33-year old caucasian previously healthy male was admitted to hospital with newly diagnosed suspicious lesions in liver and spleen. Further analyses showed additional pulmonal nodules. Biopsy revealed a tumor with predominant epithelioid cells, positive for CD31 and CD34 and negative for CD117, HHV8, AFP and CEA, classified as a HEH. Disease progressed during first line treatment with adriamycin and ifosfamide (2 cycles given). Based on a case report with encouraging results with thalidomide we treated our patient with lenalidomide, which is known to have less side effects while being more effective in the myeloma setting. After 6 courses of lenalidomide 25mg daily (21/28), regression of the splenic lesions was detected. Retrospective analysis after 9 cycles demonstrated stable disease in comparison to the recent investigation, but an overall progression of 22% according to RECIST criteria in the liver was observed. Due to the excellent tolerance we increased the daily dose to 30 mg (21/28) and 6 months later a slight regression in the lung and overall stable disease in the liver was observed. The splenic lesion disappeared completely. The patient was listed for liver transplantation and after another 4 months on lenalidomide 30 mg, he was successfully transplanted recently. Because of the remaining extrahepatic lesions it is planned to continue lenalidomide therapy in combination with the immunosuppressant rapamycine. Conclusions: We report the first case of successful therapy with lenalidomide in HEH. Higher doses than 25mg seem to be more effective. We grateful thank Celgene for offering us lenalidomide for this off label use. No significant financial relationships to disclose.
AB0354 The Prevalence of Metabolic Syndrome and Hepatobiliary System Demage in Rheumatoid Arthritis Patients
Authors: I. Klymas, L. Khimion
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) often develop wide spectrum of co-morbidities and metabolic changes, particularly involving hepatobiliary system (HBS) which can influence the safety efficacy of the RA pharmacological treatment. <h3>Objectives</h3> To determine the metabolic syndrome (MC) prevalence according to WHO (1998) and IDF (2005) classifications and its influence on HBS damage development in RA patients. <h3>Methods</h3> We investigated MS criteria and state of the HBS in 126 RA patients (102 women and 24 men, average age 43,82±2,8 years) and 30 subjects (control group) without autoimmune and inflammatory diseases (25 women and 5 men, average age 42,4±2,6 years). RA was diagnosed according to ARA criteria (1987); patients with hepatitis, alcohol abuse, &gt;55 years old were not included. MS was diagnosed according to WHO (1998) and IDF (2005) criteria; HBS was investigated by ultrasound technique and biochemistry tests. <h3>Results</h3> Three criteria of MS according to WHO classification were diagnosed in 28,75% RA patients and 10,0% of control group (p&lt;0,01), 2 criteria - in 12,70% patients and 3,33% of the control group (p&lt;0,05); according to IDF classification 3 MS criteria were found in 28,57% RA patients and 10,0% healthy subject (p&lt;0,01); 2 criteria - in 15,08% patients and 3,33% of control group (p&lt;0,05). In 91,4% RA patient with MS the signs of HBS damage were diagnosed by ultrasound: most frequently liver steatosis was found (grade II- in 50,0% and grade III - in 31,25% of patients). The same changes of liver were diagnosed less frequently in patients with RA without MS (20,0% and 13,85% accordingly, p&lt;0,05), in this group less severe liver damage (liver steatosis grade I) was the most frequent diagnosis (found in 40,0% of the group). <h3>Conclusions</h3> Both WHO (1998) and IDF (2005) classification MS criteria have the same diagnostic value for the RA patients. MS develops significantly more frequent in patients with RA than in control group at the same age group (&lt;55 years old). The combination of 2 and 3 MS criteria is characteristic for RA patients. RA patients with MS demonstrate more advanced liver steatosis comparing to RA patients without MS. <h3>Disclosure of Interest</h3> None declared
The interface between undergraduate and graduate medical education
Authors: W. D. Holden
Journal: JAMA (1979)

The principal current problem related to the interface between undergraduate and graduate medical education is the lack of preparation of graduating medical students to assume many of the patient-care responsibilities required in certain graduate programs. There are two sides to the interface, and both require attention if the problem is to be resolved. The educational quality of the generally permissive fourth year of medical school should be examined in terms of the need for medical schools to prepare students for graduate educational programs. An effective broad first year of graduate medical education requires the development of institutional policy by all clinical departmental directors jointly and the delegation of operational responsibility to a small group of professionals.  ( JAMA 241:1148-1150, 1979)
Advances in the Study of SR Protein Family
Authors: Xiaoyun Ma, Fuchu He
Journal: Genomics Proteomics & Bioinformatics (2003)

Abstract The name of SR proteins is derived from their typical RS domain that is rich in serine (Ser, S) and arginine (Arg, R). They are conserved in evolution. Up to now, 10 members of the SR protein family have been identified in humans. SR proteins contain one or two RNA binding motifs aside from the RS domain, and also possess special biochemical and immunological features. As to the functions of SR proteins, they facilitate the recruitment of the components of splicesome via protein-protein interaction to prompt the assembly of early splicesome; while in alternative splicing, tissue-specifically expressed SR protein along with the relative ratio of SR protein and heterogeneous nuclear ribonucleoprotein (hnRNP) is composed of two main regulative mechanisms for alternative splicing. Almost all of the biochemical functions are regulated by reversible phosphorylation.
PWE-078 Clinical factors predicting complicated elective cholecystectomy and validation of a scoring system
Authors: M Orizu, A Rooney, P Glen
Journal: Gut (2015)

<h3>Introduction</h3> It is recommended by professional bodies that the day surgery target for cholecystectomies should be 60% of cases. Selection for day surgery units and ambulatory care hospitals is important as these may be off site from the acute hospital, and this remains an operation with potentially life threatening complications. We wished to assess clinical factors predicting complex cholecystectomy and test a scoring system on a second cohort of patients. <h3>Method</h3> Patients undergoing cholecystectomy at Glasgow’s two ambulatory care hospitals were identified from the theatre data collection programme. In the first cohort we compared patients failing day surgery with similar numbers of consecutive uncomplicated patients. In the second cohort we tested a scoring system based on these results to assess sensitivity and specificity. <h3>Results</h3> Comparing 34 patients failing day surgery laparoscopic cholecystectomy (LC), with 39 uncomplicated LC, a number of factors were evident in different proportions between the groups, of which previous cholecystitis, previous jaundice and thickened gallbladder were significant. Patients in the second cohort were given a score of 0–5 based on number of factors present (previous jaundice, ERCP, pancreatitis, cholecystitis and thickened gallbladder). One hundred consecutive patients were assessed. Patients were stratified as having 0–1 factors present or &gt;2 factors present. Sensitivity and specificity for &gt;2 factors present in identifying complicated cholecystectomies was 75% and 80%. <h3>Conclusion</h3> Cholecystectomy remains an operation associated with complications of bile leak and conversion to open. This simple preoperative scoring system may help direct patients to specialist surgeons or acute hospitals. <h3>Disclosure of interest</h3> None Declared.
Coronary artery bypass grafting for postinfarction angina pectoris.
Authors: Kouchoukos Nt, Murphy S, Philpott T, Pelate C, Marshall Wg
Journal: Circulation (1989)

The variables that predict increased operative risk and postoperative morbidity among patients who undergo coronary artery bypass grafting (CABG) early after myocardial infarction for persistent or recurrent ischemia are incompletely defined. In a recent 3-year interval (1985-1987), 240 patients underwent CABG within 30 days of a documented myocardial infarction. Thirty-day mortality was 3.3% (eight patients). Twenty variables were examined by univariate and multivariate analysis for their effects on early mortality. Left main coronary artery disease (p = 0.0003), female sex (p = 0.0059), and preoperative left ventricular dysfunction (increased left ventricular wall motion score) (p = 0.0135) were significant independent predictors of increased 30-day mortality. Postoperative inotropic support for low cardiac output was required for 55.6% of patients operated upon within 24 hours of infarction as compared with 11.6% of patients operated upon between 1 and 30 days (p less than 0.01). Significantly more patients undergoing emergent CABG required postoperative intra-aortic balloon pumping and inotropic support than those patients who underwent urgent or elective operation (23.8% vs. 4.6% and 52.4% vs. 10%, respectively) (p less than 0.01). Other studies confirm that preoperative left ventricular dysfunction, presence of cardiogenic shock, or intra-aortic balloon pumping are important predictors of operative risk. Other variables that may be important include advanced age, female sex, left main coronary artery disease, and anterior transmural infarction. The timing and urgency of operation have not been shown to be significant and independent determinants of increased operative risk.(ABSTRACT TRUNCATED AT 250 WORDS)
Cost-effectiveness: let's get "real".
Authors: S R Lemkin
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.687 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636797 Cost-effectiveness: let's get "real". S R LemkinxS R LemkinSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.687 PDF "Cost-effectiveness: let's get "real".." Journal of Clinical Oncology, 14(2), pp. 687–688© 1996 by American Society of Clinical Oncology
Medicaid records and the psychiatric private sector
Authors: B B Perlman, A H Schwartz, J C Thornton, M Paris, W Mazanitis
Journal: American Journal of Psychiatry (1980)

The authors report a study or records maintained by private practitioners for their Medicaid patients. The quality of record keeping in general fell far short of Medicaid requirements. Board-certified or hospital-affiliated psychiatrists kept better charts than those who did not have these credentials. Educational background did not correlate with extent of record keeping.
Single Unit Transfusions
Authors: G R ELLIS, J R BROWN
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infertility after the pill.
Authors: D H Kohn
Journal: BMJ (1972)

Infertility after the PillA disquieting feature of treatment with oral contraceptives is receiving increasing attention among gynaecologists.This is that some women, on discontinuing the use of oral contraceptives, do not experience a normal return to menses, authors remark on the endometrial atrophy induced by progestogen-oestrogen mixtures, and it is possible that an element in post-pill amenorrhoea is end-organ resistance.An endometrial fibrosis like that found in Asherman's syndrome of traumatic amenorrhoea renders the uterus incapable of responding to ovarian hormones.Fortunately more than half the women with post-pill NO.
Mammalian Chromosomes &lt;italic&gt;in Vitro&lt;/italic&gt;. VII. Heteroploidy in Human Cell Strains&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: T. C. Hsu, Paul S. Moorhead
Journal: JNCI Journal of the National Cancer Institute (1957)

Mammalian Chromosomes in Vitro. VII. Heteroploidy in Human Cell Strains T. C. Hsu, T. C. Hsu Section of Cytology, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas, and Tissue Culture Laboratory, The University of Texas Medical Branch, Galveston, Texas Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul S. Moorhead Paul S. Moorhead Section of Cytology, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas, and Tissue Culture Laboratory, The University of Texas Medical Branch, Galveston, Texas Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 3, March 1957, Pages 463–471, https://doi.org/10.1093/jnci/18.3.463 Published: 01 March 1957 Article history Received: 06 November 1956 Published: 01 March 1957
RBC choline and renal disorders during lithium treatment
Authors: D F Gutterman, E I Correa, J R DePaulo, J T Coyle
Journal: American Journal of Psychiatry (1985)

The authors measured RBC choline level, plasma choline level, and renal concentrating ability in 26 lithium-treated patients, seven psychiatric control subjects, and seven normal control subjects. An analysis of variance revealed no significant relationship between renal concentrating ability and either RBC choline level or RBC/plasma choline ratio.
The Action of &lt;italic&gt;N&lt;/italic&gt;-2-Fluorenylacetamide in the Syrian Golden Hamster&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Giuseppe Della Porta, Philippe Shubik, Vieri Scortecci
Journal: JNCI Journal of the National Cancer Institute (1959)

N-2-Fluorenylacetamide was fed at a 0.04 percent level in the diet to female and male Syrian golden hamsters for 40 or 26 weeks. A high incidence of benign cholangiomatous lesions and some cholangiocarcinomas were seen. Outside of the liver, only 1 colonic adenocarcinoma, 1 leiomyosarcoma, and 1 generalized lymphoma were observed that were not believed to be related to the experimental diet. No parenchymal liver-cell tumors were observed. No definite differences between the male and female response were noted. The pathological findings are discussed in the light of their histopathogenesis.
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Authors: Edurne Arriola, Matthew Wheater, Ian Galea, Nadia Cross, Tom Maishman, Debbie Hamid, Louise Stanton, Judith Cave, Tom Geldart, Clive Mulatero, Vannessa Potter, Sarah Danson, Pennella J. Woll, Richard Griffiths, Luke Nolan, Christian Ottensmeier
Journal: Journal of Thoracic Oncology (2016)

ObjectivesOur aim was to evaluate the safety and efficacy of ipilimumab combined with standard first-line chemotherapy for patients with extensive-stage SCLC.MethodsPatients with chemotherapy-naive extensive-stage SCLC were treated with carboplatin and etoposide for up to six cycles. Ipilimumab, 10 mg/kg, was given on day 1 of cycles 3 to 6 and every 12 weeks. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, and immune-related response criteria. The primary end point was 1-year progression-free survival (PFS) according to RECIST. Secondary end points included PFS according to immune-related PFS and overall survival. Autoantibody serum levels were evaluated and correlated with clinical outcomes.ResultsA total of 42 patients were enrolled between September 2011 and April 2014; 39 were evaluable for safety and 38 for efficacy. Six of 38 patients (15.8% [95% confidence interval (CI): 7.4–30.4]) were alive and progression-free at 1-year by RECIST. Median PFS was 6.9 months (95% CI: 5.5–7.9). Median immune-related PFS was 7.3 months (95% CI: 5.5–8.8). Median overall survival was 17.0 months (95% CI: 7.9–24.3). Of the patients evaluable for response, 21 of 29 (72.4%) achieved an objective response by RECIST and 28 of 33 (84.8%) achieved an objective response by the immune-related response criteria. All patients experienced at least one adverse event; at least one grade 3 or higher toxicity developed in 35 of 39 patients (89.7%); in 27 patients (69.2%) this was related to ipilimumab. Five deaths were reported to be related to ipilimumab. Positivity of an autoimmune profile at baseline was associated with improved outcomes and severe neurological toxicity.ConclusionsIpilimumab in combination with carboplatin and etoposide might benefit a subgroup of patients with advanced SCLC. Autoantibody analysis correlates with treatment benefit and toxicity and warrants further investigation.
Tc-99m Infecton scan in possible pelvic inflammatory disease.
Authors: RAJNISH SHARMA, ANUPAM MONDAL, MANISHA SHARMA, MANJU POPLI, M. CHOPRA, KISHAN SAWROOP, RAVI KASHYAP
Journal: Clinical Nuclear Medicine (2001)

Tc-99m Infecton imaging was used to examine patients thought to have pelvic inflammatory disease (PID) based on clinical and sonographic findings. Twenty-one patients with PID had Tc-99m Infecton scans. Eleven patients underwent a second radionuclide scan after 1 month of antibiotic treatment. The diagnosis of PID was confirmed by laparoscopy in one patient who was later found to have a tubercular infection. In the remaining patients, the diagnosis was based on uterine tenderness, fever and lower abdominal pain that responded to antibiotics, and ultrasound findings. These patients had infection of the uterus, fallopian tubes, the cul-de-sac, or all of these. The Tc-99m Infecton scan appears to be useful in the diagnosis of possible PID and is recommended after a complete course of antibiotics for monitoring treatment response.
Antibody-Dependent Lymphocyte Cytotoxicity Against Cells Expressing Epstein—Barr Virus Antigens
Authors: Gary R. Pearson, Thomas W. Orr
Journal: JNCI Journal of the National Cancer Institute (1976)

Antibody-dependent lymphocyte cytotoxicity (ADLC) was demonstrated against Epstein-Barr virus (EBV)-infected RAJI cells with peripheral with peripheral blood lymphocytes from EBV-infected donors. No cytotoxic activity was detected against unifected RAJl cells. The results indicated that this antibody-mediated cytotoxic reaction was directed against the same EBV-induced membrane antigens (MA) previously defined by the membrane immunofluorescence (MF) assay. Antibody to EBV-associated early antigens did not participate in this in vitro reaction. Antibody titers to EBV-induced MA were significantly higher by the ADLC assay in comparison with the MF test. A preliminary study showed no relationship between high antibody titers and the presence of EBV-associated malignancies. The possible in vivo significance of this immune reaction was discussed.
Patients' perceptions
Authors: A. G Parker
Journal: BMJ (2009)

OBJECTIVE: To examine the association between musculoskeletal pain and smoking. DESIGN: Cross sectional, national interview survey. SETTING: All individuals in a representative sample of households in Norway in 1985. SUBJECTS: A total of 6681 persons aged 16 to 66 years old. people in institutions were not included. OUTCOME MEASURES: Gender specific and age specific prevalence rates for pain in the cervical region/upper limbs, back, and lower limbs. RESULTS: Current smoking was independently associated with musculoskeletal pain (odds ratio (OR) 1.69; 95% confidence interval (95% CI) 1.45, 1.97) after adjustment for gender, age, comorbidity, mental distress, lifestyle factors, and occupation related factors. The association was of similar strength regarding cervical/upper limb pain (OR 1.87; CI 1.56, 2.25) and back pain (OR 1.84; CI 1.50, 2.25) but weaker in respect of lower limb pain (OR 1.37; CI 1.10, 1.71). Musculoskeletal pain was often present in more than one site. CONCLUSION: Smoking was significantly associated with musculoskeletal pain after adjustment for other relevant factors.
Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use
Authors: Kathleen F. Kerr, Marshall D. Brown, Kehao Zhu, Holly Janes
Journal: Journal of Clinical Oncology (2016)

The decision curve is a graphical summary recently proposed for assessing the potential clinical impact of risk prediction biomarkers or risk models for recommending treatment or intervention. It was applied recently in an article in Journal of Clinical Oncology to measure the impact of using a genomic risk model for deciding on adjuvant radiation therapy for prostate cancer treated with radical prostatectomy. We illustrate the use of decision curves for evaluating clinical- and biomarker-based models for predicting a man’s risk of prostate cancer, which could be used to guide the decision to biopsy. Decision curves are grounded in a decision-theoretical framework that accounts for both the benefits of intervention and the costs of intervention to a patient who cannot benefit. Decision curves are thus an improvement over purely mathematical measures of performance such as the area under the receiver operating characteristic curve. However, there are challenges in using and interpreting decision curves appropriately. We caution that decision curves cannot be used to identify the optimal risk threshold for recommending intervention. We discuss the use of decision curves for miscalibrated risk models. Finally, we emphasize that a decision curve shows the performance of a risk model in a population in which every patient has the same expected benefit and cost of intervention. If every patient has a personal benefit and cost, then the curves are not useful. If subpopulations have different benefits and costs, subpopulation-specific decision curves should be used. As a companion to this article, we released an R software package called DecisionCurve for making decision curves and related graphics.